UroGen Pharma is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.91 – an increase of 7.88% over the previous week. UroGen Pharma employs 217 staff and has a trailing 12-month revenue of around $89.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.91 |
|---|---|
| 52-week range | $10.60 - $20.70 |
| 50-day moving average | $12.45 |
| 200-day moving average | $14.59 |
| Wall St. target price | $39.93 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.91 from 2024-11-22
| 1 week (2024-11-18) | 7.88% |
|---|---|
| 1 month (2024-10-25) | -1.57% |
| 3 months (2024-08-23) | -15.89% |
| 6 months (2024-05-24) | -10.05% |
| 1 year (2023-11-24) | -8.03% |
|---|---|
| 2 years (2022-11-23) | 55.08% |
| 3 years (2021-11-24) | 12.76 |
| 5 years (2019-11-22) | 29.6 |
| Revenue TTM | $89.4 million |
|---|---|
| Gross profit TTM | $56.7 million |
| Return on assets TTM | -21.12% |
| Return on equity TTM | -1481.26% |
| Profit margin | -129.11% |
| Book value | $0.61 |
| Market Capitalization | $487.4 million |
TTM: trailing 12 months
We're not expecting UroGen Pharma to pay a dividend over the next 12 months.
Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $10.6001 up to $20.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.126. This would suggest that UroGen Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.